Time filter

Source Type

Dufies M.,University of Nice Sophia Antipolis | Giuliano S.,University of Nice Sophia Antipolis | Giuliano S.,Center Scientifique Of Monaco Monaco | Ambrosetti D.,Nice University Hospital Center | And 20 more authors.
Cancer Research | Year: 2017

Sunitinib is an antiangiogenic therapy given as a first-line treatment for renal cell carcinoma (RCC). While treatment improves progression-free survival, most patients relapse. We hypothesized that patient relapse can stem from the development of a lymphatic network driven by the production of the main growth factor for lymphatic endothelial cells, VEGFC. In this study, we found that sunitinib can stimulate vegfc gene transcription and increase VEGFC mRNA half-life. In addition, sunitinib activated p38 MAPK, which resulted in the upregulation/activity of HuR and inactivation of tristetraprolin, two AU-rich element binding proteins. Sunitinib stimulated a VEGFC-dependent development of lymphatic vessels in experimental tumors. This may explain our findings of increased lymph node invasion and new metastatic sites in 30% of sunitinib-treated patients and increased lymphatic vessels found in 70% of neoadjuvant treated patients. In summary, a therapy dedicated to destroying tumor blood vessels induced the development of lymphatic vessels, which may have contributed to the treatment failure. © 2017 American Association for Cancer Research.

Loading Center Scientifique Of Monaco Monaco collaborators
Loading Center Scientifique Of Monaco Monaco collaborators